Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma
ChiCTR2100045659Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Jul 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Surgical R0 resection rate. Started Jul 2020; status: recruiting.
02
Drugs
sintilimabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100045659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045659.